Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for coronary artery disease, though its precise role in disease progression continues to emerge. This study leverages ...

Introduction: Cisplatin resistance is a major challenge in ovarian cancer therapy, particularly for high-grade serous ovarian cancer (HGSOC). DNA topoisomerase IIα (TOP2A) relates to cancer drug ...

Fintel reports that on October 28, 2025, Evercore ISI Group maintained coverage of Confluent (NasdaqGS:CFLT) with a Outperform recommendation. Analyst Price Forecast Suggests 7.54% Upside As of ...

Confluent (NASDAQ:CFLT) is gearing up to announce its quarterly earnings on Monday, 2025-10-27. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...